Reddy Sanjana, Barkhane Zineb, Elmadi Jalal, Satish Kumar Lakshmi, Pugalenthi Lakshmi Sree, Ahmad Mahlika
Obstetrics and Gynaecology, Bogomolets National Medical University, Kiev, UKR.
Research, Université Hassan II, Faculté de Médecine et de Pharmacie de Casablanca, Casablanca, MAR.
Cureus. 2022 Apr 6;14(4):e23901. doi: 10.7759/cureus.23901. eCollection 2022 Apr.
Breast cancer (BC) is defined as an uncontrolled growth of breast cells that affected 2.3 million women in 2020 alone. Until a few years earlier, radiotherapy and chemotherapy were the most commonly used treatments in treating BC; however, many trials and studies were conducted to test the competence of cyclin-dependent kinases 4/6 (CDK4/6) in arresting the cell cycle, and it was found that they were highly influential in halting the disease from progressing. Palbociclib, ribociclib, and abemaciclib are the three drugs that have been approved by the US Food and Drug Administration (FDA) and are even more efficient when used in combination with aromatase inhibitors and fulvestrant. This article aimed to explain the effect of CDK4/6 inhibitors on tumor cells and their efficacy in combination with other drugs. We further explored the development of resistance to these treatments and future possibilities.
乳腺癌（BC）是指乳腺细胞的失控性生长，仅在2020年就影响了230万女性。就在几年前，放疗和化疗还是治疗乳腺癌最常用的方法；然而，人们进行了许多试验和研究来测试细胞周期蛋白依赖性激酶4/6（CDK4/6）在阻止细胞周期方面的能力，结果发现它们在阻止疾病进展方面具有高度影响力。帕博西尼、瑞博西尼和阿贝西利是三种已被美国食品药品监督管理局（FDA）批准的药物，与芳香化酶抑制剂和氟维司群联合使用时效果更佳。本文旨在解释CDK4/6抑制剂对肿瘤细胞的作用及其与其他药物联合使用的疗效。我们还进一步探讨了对这些治疗产生耐药性的发展情况以及未来的可能性。
